Overview of Dr. Abdelrahim
Dr. Maen Abdelrahim is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including Houston Methodist Hospital, Houston Methodist Sugar Land Hospital, Houston Methodist Willowbrook Hospital, Houston Methodist Baytown Hospital, Houston Methodist West Hospital, Houston Methodist The Woodlands Hospital, and Houston Methodist Clear Lake Hospital. He received his medical degree from Texas A&M; Health Science Center College of Medicine and has been in practice 14 years. He is one of 105 doctors at Houston Methodist Hospital and one of 38 doctors at Houston Methodist Clear Lake Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
Baylor College of MedicineResidency, Internal Medicine, 2012 - 2015
Texas A&M; Health Science Center College of MedicineClass of 2012
Certifications & Licensure
TX State Medical License 2014 - 2027
NC State Medical License 2015 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Start of enrollment: 2021 Feb 10
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- "How I Do it": Caring for Solid Organ Transplant Recipients and Candidates who Need Immune Checkpoint Inhibitors.Hiroyuki Arai, Darren Cullinan, Maen Abdelrahim, Germaine Wong, Naoka Murakami
Transplantation. 2026-10-01 - Design and development of a delayed-release dose-flexible matrix tablet of tolfenamic acid for potential application in cancer therapy.Bhanu P Dongala, Mohammad T H Nutan, Maen Abdelrahim, Mariame A Hassan, Abdullah Esmail
International Journal of Pharmaceutics. 2026-09-27 - Prognostic Impact of Baseline Circulating Tumor DNA (ctDNA) in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.Maen Abdelrahim, Abdullah Esmail, Minhal Zaidi, Nour Mustafa, Yazan Hamdaneh
Cancers. 2026-07-16
Press Mentions
Surgical Options for Cholangiocarcinoma Enhance SurvivalJuly 19th, 2024- Study Finds Daily Aspirin Use Improves Colorectal Cancer OutcomesJuly 19th, 2024
- Transplant Oncology Transforms Outcomes for Patients with Unresectable Liver TumorsJuly 23rd, 2026
Grant Support
- NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune SurveillanceTEXAS A&M UNIVERSITY2023–2026
- NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune SurveillanceTEXAS A&M UNIVERSITY2023–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: